REGENXBIO price to free cash flow RGNX

Market value divided by free cash flow over the last twelve months, since 2018.

Today, Oct 23, 2026: n/m; not a meaningful number
Last meaningful: 7.8×; Feb 2023
8-year median: 19.1×
8-year range: 6.2× to 492×
Peer median: 31.1×

REGENXBIO's price to free cash flow is not a meaningful number today: free cash flow over the last twelve months was zero, negative or not reported.

It was last meaningful in Feb 2023, at 7.8×.

On the days it had one over the last 8 years, its median was 19.1×, from 6.2× in May 2022 to 492× in Jun 2019.

Price to free cash flow over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2023	7.8×	7.8×	9.0×
2022	8.3×	6.2×	12.8×
2021	n/m a value too high to mean anything
2020	n/m a value too high to mean anything
2019	394×	18.3×	492×
2018	17.7×	16.7×	229×

Against its peers

Companies in Biotechnology nearest REGENXBIO's size, closest first, today.

Company	Price to free cash flow
RGNXREGENXBIO	n/m
MGTXMeiraGTx	84.5×
PLXProtalix BioTherapeutics	26.8×
VCELVericel	35.3×
ADMAAdma Biologics	20.5×
Peer median	31.1×

What the price to free cash flow tells you

Market value divided by free cash flow: the cash left after running the business and paying for equipment. Cash is harder to manage than accounting earnings, so many investors trust this more than PE.

Lumpy: a big year of building factories drops cash flow and inflates the ratio without the business getting worse.

More on REGENXBIO

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.